Director Shareholding

RNS Number : 7050J

Alliance Pharma PLC

06 April 2010

 



For immediate release

6 April 2010

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Director Shareholding

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that on 1 April 2010 it was advised that Thomas Casdagli, a non-executive Director of the Company, has a beneficial interest in 18,804 ordinary shares of the Company (representing 0.01% of the issued share capital) and £972 nominal of Convertible Unsecured Loan Stock in the Company ("CULS") (0.02% of the CULS in issue).  These interests arise as a result of Mr Casdagli being a partner of MVM Fund III LLP and MVM Fund III (No. 2) LLP, which between them own 19,300,000 ordinary shares in the Company and £1,000,000 nominal of CULS.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications	+ 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic / Jennie Spivey
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Brent Nabbs
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections.  Alliance's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

RDSIAMLTMBJMBFM